RxDoctor Payments Data

Noah Finkel, MD

Hospitalist · Burlington, MANPI 1831133008

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Acadia Pharmaceuticals Inc accounts for 86.1% of it on its own, with 1 other manufacturer making up the rest. Among hospitalist clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$790in general payments, 2019–2025

Across 7 payments — averaging $112.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$680
  • Neurocrine Biosciences, Inc.$110

What the payments were for

  • Food & beverage$790100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$790 in reported general payments places this provider in the 90th percentile of 599 hospitalist providers in Massachusetts.

See all hospitalist providers in Massachusetts

Medicare billing

Part B allowed, 2024
$470,739
Medicare patients
583
Services billed
3,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban415$122,980
NuplazidPimavanserin Tartrate32$83,140
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog159$19,156
JardianceEmpagliflozin56$16,852
MyrbetriqMirabegron62$14,566
XareltoRivaroxaban73$12,792
Bydureon BciseExenatide Microspheres36$12,027
Trazodone Hcl685$11,313
Gabapentin432$10,303
Atorvastatin Calcium541$10,200
ErtapenemErtapenem Sodium30$10,040
Mirtazapine310$9,162
Potassium Chloride130$7,044
Enoxaparin Sodium88$6,962
Tiotropium Bromide16$6,705

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$680$83,14032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 599 hospitalist providers in Massachusetts.

Other hospitalist in Burlington

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →